In addition, pioglitazone depletes stem cells via decreased STAT5, HIF2α, and carboxy-terminal domain 2 (CITED2) expression in chronic myeloid leukemia (CML) [227] and potentiates the effect of imatinib [227]. This evidence concerns the gene EPAS1 and chronic myelogenous leukemia, BCR-ABL1 positive.